Eli Lilly & Co.: PharmaVitae Profile

Publication Date	July 2009
Publisher	Datamonitor
Product Type	Report
Pages	103
ISBN Number	not applicable
Product Code	DAT09492

Buy this product or for assistance call +44 20 7060 7474

PDF £3,425.00$5697 | €3833

PRINT £3,485.00$5797 | €3901

FAX Order above formats by FAX

Summary

Introduction

This analysis examines the historical and forecast performance for Eli Lilly in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

Benchmark Eli Lilly's performance against key rivals in the prescription pharmaceutical sector
Assess the commercial outlook for key new launch products Effient and Byetta LAR
Evaluate Eli Lilly's ability to overcome the adverse impact of patent expiry for Zyprexa, Cymbalta and other key franchises over the period 2011-14

Content

ABOUT DATAMONITOR HEALTHCARE
About the PharmaVitae team
Chapter 1 About this profile
- PharmaVitae Explorer database
Chapter structure
- Executive summary
- Quarterly news update
- Company introduction
- Company sales
- Company financials
- Key products and competitors
- Data sourcing
- Sales data
- Analyst consensus
Chapter 2 Executive summary
- Key findings
- Prescription pharmaceutical sales and growth rate performance, 2002-14
- Financial performance, 2002-14
- Eli Lilly: PharmaVitae forecasts at a glance
- Strategic insight
- The looming challenge of 'Years Y and Z'
- Strategies to weather the loss of sales
- Investment following 'Year X'
- Looking to external sources of growth
- Outlook heavily dependent upon Effient and Byetta LAR
- Out-sourcing spreads risk and leverages expertise
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- Table of figures
Chapter 3 Quarterly news update
- Key findings
- Product developments
- Deals and alliances
- Product deals
- Technology deals
- M&A activity
- Company announcements
- Future product milestones
Chapter 4 Company introduction
- Key findings
- Background
- Key corporate developments
- M&A history
- Advanced Cardiovascular Systems acquired
- Hybritech acquired
- DowElanco formed
- Devices for Vascular Intervention acquired
- Origin Medsystems acquired
- Sphinx Pharmaceuticals acquired
- Guidant spun-out
- Remaining medical device businesses divested
- PCS Health Systems acquired
- Hybritech divested
- DowElanco holding sold
- PCS Health Systems sold
- Applied Molecular Evolution acquired
- ICOS acquired
- Hypnion acquired
- Ivy Animal Health acquired
- SGX Pharmaceuticals acquired
- ImClone Systems acquired
- M&A strategy
- Current corporate structure
- Pharmaceuticals
- Elanco Animal Health
- Pharmaceuticals business unit structure
Chapter 5 Company sales
- Key findings
- Prescription pharmaceutical sales and growth rate analysis, 2002-14
- Product analysis
- Product analysis, 2002-08
- Product analysis, 2008-14
- Therapy area analysis
- Geographic analysis
- Launch/core/expiry analysis
- Explanation of launch/core/expiry analysis
- Launch analysis, 2008-14
- Core analysis, 2008-14
- Expiry analysis, 2008-14
- Launch/core/expiry configuration, 2008-14
- Molecule type analysis
- Externalization analysis
Chapter 6 Company financials
- Key findings
- Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08
- Operating costs and profit analysis
- Operating costs and profit analysis, 2002-08
- Operating cost ratio and profit margin analysis, 2002-08
- Operating cost ratio and profit margin analysis, 2008-14
- Operating costs and profit analysis, 2008-14
Chapter 7 Key products and competitors
- Key findings
- Overview
- Central nervous system
- Zyprexa
- Overview
- Sales forecast
- Sales have slipped due to side effect concerns
- Further gradual decline before US generics in 2011
- Zypadhera delayed by side effect issues
- Cymbalta
- Overview
- Sales forecast
- Commercial success despite competition from Effexor and generic selective serotonin reuptake inhibitors (SSRI)
- New indications have significantly lifted sales
- Key growth driver to turn to decline in 2013
- Endocrine, metabolic & genetic disorders
- Byetta franchise
- Overview
- Sales forecast
- First integrin mimetic to market
- Competition challenges sales growth
- Byetta LAR offers once-weekly convenience
- Humalog franchise
- Overview
- Sales forecast
- Insulin is the cornerstone of diabetes treatment
- New Humalog formulations have driven further market expansion
- Market leading position lost to new entrants
- Scope for further growth is limited
Chapter 8 Appendix
- R&D pipeline
- Collaboration/ other revenue reconciliation
- 2002-08
- 2008-14
- References
- Abbreviations
- Exchange rates
- About Datamonitor
- About Datamonitor Healthcare
- Datamonitor consulting
- Disclaimer
- Table 1: Eli Lilly - PharmaVitae forecasts at a glance
- Table 2: Eli Lilly key product developments, Q1-Q2 2009
- Table 3: Eli Lilly product deals and alliances, Q1-Q2 2009
- Table 4: Eli Lilly technology deals and alliances, Q1-Q2 2009
- Table 5: Eli Lilly M&A activity, Q1-Q2 2009
- Table 6: Eli Lilly company announcements, Q1-Q2 2009
- Table 7: Eli Lilly future product milestones, 2009-11
- Table 8: Eli Lilly product portfolio overview ($m), 2002-08
- Table 9: Eli Lilly product portfolio overview ($m), 2008-14
- Table 10: Eli Lilly prescription pharmaceutical sales by therapy area ($m), 2008-14
- Table 11: Eli Lilly prescription pharmaceutical sales by geographic region ($m), 2008-14
- Table 12: Eli Lilly launch portfolio overview ($m), 2008-14
- Table 13: Eli Lilly core portfolio overview ($m), 2008-14
- Table 14: Eli Lilly expiry portfolio overview ($m), 2008-14
- Table 15: Eli Lilly prescription pharmaceutical sales by molecule type ($m), 2008-14
- Table 16: Eli Lilly prescription pharmaceutical sales by source ($m), 2008-14
- Table 17: Total Eli Lilly sales by business unit ($m), 2002-08
- Table 18: Eli Lilly operating revenue/cost analysis ($m), 2002-08
- Table 19: Eli Lilly operating cost ratio analysis (% of total revenues), 2002-08
- Table 20: Eli Lilly operating cost ratio analysis (% of total revenues), 2008-14
- Table 21: Eli Lilly operating revenue/cost analysis ($m), 2008-14
- Table 22: Key products overview
- Table 23: Zyprexa: overview
- Table 24: Zyprexa: sales forecast ($m), 2008-14
- Table 25: Cymbalta: overview
- Table 26: Cymbalta: sales forecast ($m), 2008-14
- Table 27: Byetta: overview
- Table 28: Byetta franchise: sales forecast ($m), 2008-14
- Table 29: Humalog franchise: overview
- Table 30: Humalog franchise: sales forecast ($m), 2008-14
- Table 31: Eli Lilly's R&D pipeline (Phase I-registration)
- Table 32: Total Eli Lilly sales by business unit ($m), 2002-08
- Table 33: Total Eli Lilly sales by business unit ($m), 2008-14
- Table 34: Exchange rates, 2009
List of Figures
- Figure 1: The PharmaVitae Explorer
- Figure 2: Eli Lilly prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14
- Figure 3: Eli Lilly's financial performance ($m), 2002-14
- Figure 4: Impact of 'Year XYZ' expiries on Eli Lilly's total pharmaceutical sales
- Figure 5: Eli Lilly year-on-year pharmaceutical revenue growth split by source, 2008-14
- Figure 6: Sensitivity of Eli Lilly's pharmaceutical revenue outlook on key assumptions
- Figure 7: Eli Lilly SWOT analysis
- Figure 8: M&A/divestment history
- Figure 9: Current corporate structure
- Figure 10: Current corporate structure
- Figure 11: Pharmaceuticals business unit structure
- Figure 12: Eli Lilly prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14
- Figure 13: Key product sales ($m), 2002-14
- Figure 14: Eli Lilly key sales growth drivers and resistors ($m), 2002-08
- Figure 15: Eli Lilly key sales growth drivers and resistors ($m), 2008-14
- Figure 16: Eli Lilly prescription pharmaceutical sales by therapy area ($m), 2002-14
- Figure 17: Eli Lilly prescription pharmaceutical sales by geographic region ($m), 2002-14
- Figure 18: Eli Lilly launch/core/expiry configuration ($m), 2008-14
- Figure 19: Eli Lilly prescription pharmaceutical sales by molecule type ($m), 2002-14
- Figure 20: Eli Lilly prescription pharmaceutical sales by source ($m), 2002-14
- Figure 21: Eli Lilly operating revenue/cost analysis ($m), 2002-14